Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01290549 (Clinical Trial / DCDS4501A / Polatuzumab Vedotin / RG-7596)

Study Title
A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (NCT01290549)

Trial Description
This is a Phase I, multicenter, open-label, dose-escalation study of DCDS4501A (also known as polatuzumab vedotin or RG-7596) administered as a single agent by IV infusion to patients with relapsed or refractory hematologic malignancies. In Phase Ib, patients will receive DCDS4501A in combination with rituximab.

This trial is sponsored by Genentech.

Study Data

  • Conditions:
    • Non-Hodgkin’s Lymphoma
    • Chronic Lymphocytic Leukemia
  • Interventions:
    • Drugs used in this trial
  • Phase: I
  • Enrollment: 95
  • Start: March 2011
  • Primary Completion: June 2012
  • Last verified: February 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 13, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar